Basal cell and squamous cell carcinomas, grouped together under the term nonmelanoma skin cancer (NMSC), are a major dermatologic problem. In the United States alone, over 3.5 million new cases of this malignancy are diagnosed each year ([@R37]). This far exceeds the 1.66 million cases of cancer in all other organs combined ([@R44]). In contrast to most other malignancies in which the incidence has either stabilized or begun to decline, the likelihood of developing a NMSC continues to grow ([@R37]). Moreover, NMSCs are developing in younger and younger age groups; it is not uncommon to see women in their 20s and 30s developing their first NMSC ([@R10]). The epidemic of skin cancer represents a major public health issue and is a tremendous cost to healthcare systems in the United States and around the world ([@R36]).

Because of the prevalence of the problem, there has been great interest in developing methods by which skin cancers can be prevented. The vast majority of skin cancers are caused by overexposure to ultraviolet radiation from the sun and artificial light sources. Thus, much of the effort to prevent skin cancer has centered on avoidance of excessive sun exposure, education about the deleterious effects of artificial tanning bed use, advice that outdoor activities should be conducted as much as possible in shaded areas, and recommendations that protective hats and long-sleeved clothing should be worn outside. But the mainstay of skin cancer prevention has focused on advising people to apply sunscreens regularly. While not to deny the importance of these topical agents, the few studies that have been conducted evaluating their efficacy for skin cancer prevention have shown only a modest reduction in actinic keratoses (AKs) ([@R50]) and squamous cell carcinomas (SCCs) of the skin ([@R22]) and no statistically significant reduction in the incidence of basal cell carcinomas (BCCs) ([@R22]). In addition, there is inconsistent patient compliance with sunscreen use, even in organ transplant recipients who are at greatest risk for UV-induced NMSCs ([@R42]). Furthermore, large amounts of sunscreen are required to achieve the full sunburn protective factor (SPF) value on the product label, and patients only use about 25% of that amount when applying sunscreens ([@R15]). Finally, there is no effect of sunscreens on prior UV damage to the skin. Thus, existing methods are inadequate and additional measures are required to retard the rising incidence of NMSC. Identification and implementation of chemopreventive agents against skin cancer represent one of the major unmet needs in photodermatology.

Cyclooxygenases and Chemoprevention {#S1}
===================================

There is strong evidence from experiments in animal models and epidemiologic studies that cyclooxygenases are intimately involved in the promotion and progression stages of NMSCs, and therefore, may be excellent targets for the prevention of NMSCs ([@R38]). There are two major cyclooxygenase isoforms, cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). COX-1 is constitutively expressed in most cell types. COX-2 is not normally expressed in most tissues, but can be induced to do so by a variety of stimuli including growth factors, cytokines, and tumor promoters ([@R38]). Ultraviolet radiation is a known stimulus for COX-2 expression in the epidermis (see [Figure](#F1){ref-type="fig"}) ([@R1]; [@R7]; [@R16]; [@R35]). Cyclooxygenases are prostaglandin-endoperoxide synthases that catalyze the formation of prostaglandins from arachidonic acid ([@R6]). UV-induced COX-2 expression increases PGE2, one of the major cyclooxygenase products implicated in NMSC development. PGE2 binds to four G-protein coupled receptors, EP1 - EP4, on the surface of cells, including keratinocytes ([@R40]). Each receptor activates distinct signaling pathways, although there is extensive crosstalk between the pathways. EP1, EP2, and EP4 have all been linked to UV induced skin carcinogenesis in animal models. PGE2 has been shown to increase tumor cell proliferation, inhibit apoptosis, stimulate an inflammatory response, promote immunosuppression, and facilitate tumor invasion. All of these functional activities of PGE2 are important contributors to the development of UV-induced SCCs of the skin.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are medications that are widely used in clinical practice for the treatment of rheumatoid arthritis and osteoarthritis. These agents act by inhibiting the action of the COX-1 and COX-2 enzymes and thus impair production of PGE2. NSAIDs have been employed to investigate the role of cyclooxygenases in disease ([@R17]; [@R52]). Examples of FDA approved agents that non-selectively inhibit both COX-1 and COX-2 include sulindac, naproxen, and indomethacin. Celecoxib, on the other hand, has a much greater effect on COX-2 than on COX-1 ([@R24]). When used on a chronic basis, COX-2 selective inhibitors have been associated with adverse cardiovascular events including heart attack and stroke ([@R25]; [@R45]; [@R46]). Cardiovascular adverse events are also more common with some, but not all, non-selective NSAIDs that block both COX-1 and COX-2; naproxen may even have a slight protective effect ([@R19]; [@R34]). Other toxicities of NSAIDs include nausea, gastrointestinal pain and hemorrhage ([@R13]). Preclinical data has shown that nitric oxide (NO) releasing NSAIDs such as NO-naproxen and NO-sulindac have much less gastrointestinal toxicity compared to their non-NO releasing counterparts, i.e. naproxen and sulindac ([@R5]; [@R48]). Furthermore, NO-releasing NSAIDs also augment the expression of antioxidant response element genes which may further augment their chemopreventive activity.

Animal Models {#S2}
=============

Convincing evidence to support the concept that cyclooxygenases play an essential role in UV-induced skin carcinogenesis has been obtained from experiments in animal models. In UV-induced skin tumorigenesis experiments in which wild type mice were compared to animals with a heterozygous mutation in either the COX-1 or COX-2 gene, COX-2 deficient mice had a significant reduction in SCCs compared to wild type mice, whereas those mice with a deficiency in COX-1 were unaffected by the deficiency and behaved exactly like wild type mice ([@R18]). In contrast, both COX-1 and COX-2 appear to participate in the development of BCCs. Ptch^+/-^ mice are known to develop large numbers of BCCs following exposure to ultraviolet radiation ([@R49]). When mutations in the COX-1 and COX-2 genes were backcrossed onto this strain and those mice were chronically exposed to UV-irradiation, both the COX-1 and COX-2 deficient mice, developed significantly fewer BCCs than Ptch^+/-^ mice without cyclooxygenase deficiencies. The conclusion from these studies was that COX-2, but not COX-1, is important for UV-induced SCCs, whereas both COX-1 and COX-2 contribute to BCC development. Thus, cyclooxygenase participation differs depending on the type of malignancy. In other studies, it has been shown that COX-1 diminishes apoptosis in UV-induced squamous cell carcinomas, but does not inhibit tumor cell proliferation or tumor development ([@R32]). Although it has not yet been investigated, this may be different in animal models of UV-induced basal cell carcinoma.

Experiments have also been conducted in animal models to determine whether selective COX-2 inhibitors and nonselective COX-1 and COX-2 inhibitors might be effective chemopreventive agents for UV induced NMSCs ([@R16]; [@R31]; [@R39]; [@R49]). Those studies have shown that the COX-2 inhibitor celecoxib will block UV-induced SCC development in mice. The nonselective COX-1 and COX-2 inhibitors, naproxen, indomethacin, sulindac and the nitric oxide releasing derivative, NO-sulindac, have also been observed to dramatically reduce the number of UV-induced skin tumors ([@R3]; [@R9]; [@R29])

Over the past several years, a number of natural and dietary agents have been identified that are potent chemopreventive agents for UV-induced skin cancers. Many of these natural and dietary compounds contain polyphenols that have a variety of different activities. Recent studies have shown that some of these, such as grape seed proanthocyanidins, inhibit the expression of cyclooxygenase-2, and this effect is associated with a reduction in the number of UV-induced skin tumors in mice ([@R43]).

Mechanistic Studies {#S3}
===================

The mechanism by which cyclooxygenases foster the development of UV induced skin cancers has been investigated in detail, primarily by evaluating the parameters that are affected by pharmacologic inhibition of these enzymes.

It is known that PGE2 stimulates the proliferation of malignant and premalignant keratinocytes (Ansari et al. 2008; [@R39]). NSAIDs block this effect and also promote apoptosis. Consistent with this observation, sulindac is effective at attenuating expression of several markers of proliferation including c-fos, cyclins D1 and A and PCNA ([@R4]). Similarly, the reduction in UV-induced tumor formation with NO-sulindac is associated with an increase in the number of TUNEL-positive cells, increased expression of pro-apoptotic Bax and decreased expression of anti-apoptotic Bcl-2 ([@R9]). In UV-irradiated skin, there is an increase in the phosphorylation of the MAP kinases, Erk1/2, p38 and JNK1/2, which are upstream signaling molecules of cellular proliferation and inflammation. NO-sulindac blocks this activity ([@R9]).

COX-2 augments epithelial mesenchymal transition, the process by which malignant cells weaken intercellular adhesion and enhance motility, thus allowing them to penetrate into surrounding tissues (Lee et al. 2008). NO-sulindac inhibits epithelial mesenchymal transition to block the progression of UVB-induced tumors by decreasing the expression of mesenchymal markers fibronectin, N-cadherin, Snail, Slug and Twist and by increasing the epithelial cell polarity marker E-cadherin ([@R9]).

In addition to promoting the proliferation of pre-neoplastic cells and facilitating epithelial mesenchymal transition, UV-induced PGE2 production stimulates inflammation ([@R54]), one consequence of which is to promote UV-induced skin tumorigenesis ([@R53]). Topical application of celecoxib or the EP1 specific inhibitor ONO-87713 blocks both UV-induced inflammation and tumor development ([@R51]; [@R53]).

In contrast to the non-specific inflammatory response which promotes UV-induced skin tumorigenesis, there is an effective cell-mediated anti-tumor immune response that inhibits UV-induced tumor development ([@R26]). UV radiation suppresses that response ([@R20]; [@R27]; [@R41]). The nonselective COX-1 and COX-2 inhibitor, indomethacin, abrogates the immunosuppressive effects of UV radiation ([@R11]; [@R47]). DNA hypermethylation has recently been shown to be a mediator of UVB induced immune suppression and skin tumorigenesis ([@R33]). The effects of UV radiation on DNA hypermethylation can be reversed by the cyclooxygenase inhibitors indomethacin and celecoxib and by the EP2 antagonist AH6809. These agents mediate this effect by reversing the actions of PGE2 on DNA methyltransferase activity ([@R33]).

Epidemiologic Studies {#S4}
=====================

A number of epidemiologic studies support the concept that NSAIDs which inhibit cyclooxygenases have a positive effect in decreasing the risk of cutaneous NMSC ([@R8]; [@R12]; [@R21]; [@R23]). A case-control study based in Australia with a cohort of 1621 individuals, captured NSAID use ([@R8]). The incidence of SCCs and BCCs was self-reported by patients and then confirmed by medical records. Participants were also examined for AKs on the face, ears, right hand and right forearm ([@R8]). People who used NSAIDs more than two times per week for at least a year had a statistically significant lower incidence of SCCs and lower AK counts than those who had never used them or used them infrequently. In another population base case-control study from Denmark, both NMSC and melanoma risk among NSAID users were evaluated ([@R23]). The incidence of BCCs, SCCs and melanomas was identified over a period of 18 years and compared to prescription data of aspirin, nonselective NSAIDs and selective COX-2 inhibitors. The use of aspirin, nonselective NSAIDs, and COX-2 inhibitors was associated with decreased risk of SCC and melanoma. Moreover, the reduction in risk increased as the frequency and duration of NSAID use increased. No association between NSAID use and BCC was found.

While several studies support the hypothesis that NSAIDs suppress the development of UV-induced skin cancers, other reports have not found a significant association between NSAIDs and skin cancer prevention or have found the results to be inconclusive ([@R2]; [@R21]; [@R30]). A retrospective case-control study assessing the association between NSAIDs and SCCs examined self-reported NSAID use in 415 patients with histopathologically confirmed SCC ([@R2]). Study questionnaires collected information on over-the-counter and prescription NSAID use during the 10 years prior to SCC diagnosis. The results from this study showed no decrease in SCCs from NSAID use regardless of dose or duration. Another study examined data from the Skin Cancer Chemoprevention Study for an association between NSAID use with the risk of BCCs and SCCs. No significant protective effect of NSAIDs on BCCs was observed ([@R21]). Overall rates of SCC incidence were lower for NSAID users, although this may have been due to a chance association.

Translational Studies {#S5}
=====================

The consequences of UV radiation on cyclooxygenase expression in animal models are similar to that which takes place in humans. When the skin of normal volunteers is exposed to a single 1-2 times the minimal erythema dose (MED) of ultraviolet radiation from a solar simulator, a substantial increase in COX-2 expression occurs, but there is no change in COX-1 expression ([@R7]). In some individuals, this can be suppressed by pre-treatment with celecoxib ([@R35]). Moreover, immunohistological studies have shown that while COX-2 is not found in normal skin, it is present in AKs and SCCs ([@R1]). COX-2 is also expressed in the parenchyma and/or the stroma surrounding BCCs ([@R1]; [@R49]).

Because of the abundance of data from animal experiments, epidemiologic studies suggesting that NSAIDs may suppress the development of UV-induced tumors, and the findings that NSAIDs exert a protective effect in colon chemoprevention trials ([@R28]), two clinical studies have been conducted to determine whether COX-2 inhibitors might be effective preventive agents for NMSCs ([@R14]; [@R49]). One of these was a double blind, placebo-controlled trial conducted at eight U.S. academic centers ([@R14]). Two hundred forty subjects with Fitzpatrick, sun reactive skin types I-III who had 10-40 AKs at baseline and a prior histological diagnosis of at least one AK or NMSC were randomized to receive celecoxib (200 mg b.i.d.), an oral selective inhibitor of COX-2 that is FDA approved for the treatment of rheumatoid arthritis, osteoarthritis, and the adjunct treatment of familial adenomatous polyposis, or placebo. A known photosensitivity disorder, topical medications other than sunscreens or emollients, recent treatment for AKs and NSAID use other than cardioprotective doses of aspirin were exclusion criteria. Participants that enrolled in the study were primarily males. The mean age was 65 years, and all had extensive actinic damage. The mean number of NMSCs prior to entry into the study was 2.3, and the mean number of AKs at baseline was 22.4. Participants were placed on celecoxib or placebo for 9 months and were followed for an additional 2 months off medication.

There was no effect of celecoxib on the incidence of AKs. However, there was a dramatic decrease in the incidence of NMSCs. At 11 months, there was a 58% reduction in NMSCs. The difference between the celecoxib and placebo treated groups first became apparent 3 months after initiation of therapy and became statistically significant at 9 months. It should be noted that there was no rebound in the incidence of skin cancer in the 2 months after completion of celecoxib treatment, although it should be noted that the two month duration was relatively short. When BCCs and SCCs were analyzed separately, celecoxib was protective for both. There was no significant difference in serious adverse events or cardiovascular adverse events between the two groups. However, it should be noted that the major cardiovascular toxicity from COX-2 inhibitors occurs after 12-18 months, so the absence of side effects after 9 months would be expected ([@R45]).

Studies examining the chemopreventive effects of celecoxib have also been conducted in patients with basal cell nevus syndrome (BCNS) ([@R49]). Sixty BCNS patients were enrolled in a trial in which they received celecoxib or placebo for 2 years. In those individuals who had less than 15 BCCs at the initiation of study, the increase in new BCCs was only 22% compared to 48% in those who received placebo. The difference between the two groups was statistically significant.

From these studies, it is reasonable to conclude that: 1) inhibition of COX-2 is an effective means of limiting the development of cutaneous squamous cell and basal cell carcinomas; 2) that it acts at a late stage in skin tumor development based on the fact that actinic keratoses were not prevented by celecoxib treatment; and 3) celecoxib works rapidly and is highly effective.

The preclinical, epidemiologic and translational studies provide proof of principal that agents which inhibit cyclooxygenase-2 have the potential to limit the development of new NMSCs. Patients with extensive actinic damage often develop both BCC and SCC. A particularly attractive feature of NSAIDs and other agents that block COX-2 is their potential to block both types of NMSC. Whether alternatives to celecoxib, which include nonspecific COX-1 and COX-2 inhibitors such as naproxen or sulindac, topical application of cyclooxygenase inhibitors, or dietary chemopreventive agents which limit COX-2 activities can be employed on a long-term basis to stem the increase in nonmelanoma skin cancers remains to be determined.
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